---
schema_version: "secwatch.filing_event.v1"
accession: "0001701478-26-000029"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-05-13T00:09:52+00:00"
generated_at: "2026-05-13T10:05:47.653264+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Azitra Q1 net loss $3.9M; adds MD Anderson for ATR-04 trial

## Summary
- Net loss $3.9M ($1.6M R&D, $2.4M G&A); cash $10.1M at March 31, 2026.
- Added MD Anderson Cancer Center as clinical site for Phase 1/2 trial of ATR-04 targeting EGFRi-associated rash.
- Launched cosmeceutical initiative using filaggrin protein/peptide technologies for fine lines and wrinkles.
- Secured new U.S. patent for ATR-12 (Netherton syndrome); Phase 1b topline data expected H2 2026.
- Private placement financing of up to ~$10.5M (up to ~$20.9M if warrants exercised).

## SEC filing metadata
- accession: 0001701478-26-000029
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-05-13T00:09:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/0001701478-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/aztr-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701478-26-000029
- JSON: https://secwatch.observer/filing/0001701478-26-000029.json
- Plain text: https://secwatch.observer/filing/0001701478-26-000029.txt

## Key facts
- Earnings Releases
  Azitra, Inc. reported the quarter ended March 31, 2026 results: net income $3.9 million.
  - Period: the quarter ended March 31, 2026
  - Net income: $3.9 million
  - Result: reported results
  source text: Net Loss was $3.9 million for the quarter ended March 31, 2026, compared to $3.1 million for the comparable period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701478/000170147826000029/0001701478-26-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.